You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

LILLY Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for LILLY
International Patents:30
US Patents:1
Tradenames:85
Ingredients:81
NDAs:105

Drugs and US Patents for LILLY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly DICUMAROL dicumarol CAPSULE;ORAL 005509-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520-005 Dec 24, 2003 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial
Lilly KEFLET cephalexin TABLET;ORAL 050440-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly NOVRAD levopropoxyphene napsylate anhydrous CAPSULE;ORAL 012928-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly DIETHYLSTILBESTROL diethylstilbestrol TABLET, DELAYED RELEASE;ORAL 004039-006 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly MOXAM moxalactam disodium INJECTABLE;INJECTION 050550-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly FORTEO teriparatide SOLUTION;SUBCUTANEOUS 021318-002 Jun 25, 2008 AP RX Yes Yes 7,517,334 ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LILLY

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 6,797,719 ⤷  Try a Trial
Lilly CIALIS tadalafil TABLET;ORAL 021368-003 Nov 21, 2003 7,182,958*PED ⤷  Try a Trial
Lilly FORTEO teriparatide SOLUTION;SUBCUTANEOUS 021318-002 Jun 25, 2008 7,550,434 ⤷  Try a Trial
Lilly CINOBAC cinoxacin CAPSULE;ORAL 018067-002 Approved Prior to Jan 1, 1982 3,669,965 ⤷  Try a Trial
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 RE38968 ⤷  Try a Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-007 Feb 14, 2005 5,658,590*PED ⤷  Try a Trial
Lilly CIALIS tadalafil TABLET;ORAL 021368-003 Nov 21, 2003 6,140,329 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for LILLY drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Injection 1g/vial ➤ Subscribe 2005-11-14
➤ Subscribe For Injection 100 mg/vial ➤ Subscribe 2008-07-01
➤ Subscribe For Injection 1000 mg/vial ➤ Subscribe 2012-06-27
➤ Subscribe Injection 250 mcg/mL, 2.4 mL prefilled Pen ➤ Subscribe 2015-07-27
➤ Subscribe Tablets 5 mg, 10 mg and 20 mg ➤ Subscribe 2007-11-21
➤ Subscribe Delayed-release Capsules 40 mg ➤ Subscribe 2012-05-10
➤ Subscribe Capsules 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg ➤ Subscribe 2005-01-10
➤ Subscribe For Injection 200 mg/vial ➤ Subscribe 2005-11-01
➤ Subscribe For Injection 2 g/vial ➤ Subscribe 2007-08-24
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2008-02-04
➤ Subscribe For Injection 750 mg/vial ➤ Subscribe 2016-10-06
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2008-10-14
➤ Subscribe Delayed-release Capsules 20 mg, 30 mg and 60 mg ➤ Subscribe 2008-08-04
➤ Subscribe Capsules 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg ➤ Subscribe 2007-05-29
➤ Subscribe Capsules 3 mg/25 mg ➤ Subscribe 2008-05-08

Supplementary Protection Certificates for LILLY Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 CR 2014 00050 Denmark ⤷  Try a Trial PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
1539166 92323 Luxembourg ⤷  Try a Trial PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
0740668 03C0017 France ⤷  Try a Trial PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112
2782584 21C1058 France ⤷  Try a Trial PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406
0521471 C300125 Netherlands ⤷  Try a Trial PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
1441735 SPC/GB08/020 United Kingdom ⤷  Try a Trial PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
0721777 SPC/GB04/033 United Kingdom ⤷  Try a Trial PRODUCT NAME: ATOMOXETINE, OPTIONALLY IN THE FORM OF A SALT, SUCH AS THE HYDROCHLORIDE; REGISTERED: UK PL 00006/0374 20040527; UK PL 00006/0375 20040527; UK PL 00006/0376 20040527; UK PL 00006/0377 20040527; UK PL 00006/0378 20040527; UK PL 00006/0379 20040527
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.